From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

ESMO Open. 2019 Sep 8;4(5):e000548. doi: 10.1136/esmoopen-2019-000548. eCollection 2019.
No abstract available

Keywords: ALK inhibitors; alectinib; anaplastic lymphoma kinase; brigatinib; ceritinib; crizotinib; lorlatinib; tyrosine kinase inhibitors.

Publication types

  • Editorial